3 US Penny Stocks With Market Caps Over $20M

As the U.S. stock market experiences a downturn, with the S&P 500 on track to end its three-week winning streak, investors are keenly observing opportunities across various sectors. Penny stocks, though often associated with riskier ventures, continue to capture attention due to their potential for substantial returns when backed by strong financials and growth prospects. This article explores three penny stocks that stand out for their solid balance sheets and potential for growth, offering investors a chance to uncover hidden value in smaller companies.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
Inter & Co (NasdaqGS:INTR)	$4.51	$2.08B	★★★★☆☆
BAB (OTCPK:BABB)	$0.869	$6.03M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$141.58M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.91	$87.36M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.2444	$8.83M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.52	$49.5M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$0.7645	$14.19M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8899	$80.95M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.76	$413.23M	★★★★☆☆

Click here to see the full list of 712 stocks from our US Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Data I/O (NasdaqCM:DAIO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Data I/O Corporation designs, manufactures, and sells programming and security deployment systems for electronic device manufacturers globally, with a market cap of $26.78 million.

Operations: The company generates revenue of $23.46 million from its operations focused on the design, manufacturing, and sale of programming systems.

Market Cap: $26.78M

Data I/O Corporation, with a market cap of US$26.78 million, faces challenges typical of penny stocks, including recent unprofitability and shareholder dilution. The company reported declining sales in Q3 2024 at US$5.42 million compared to the previous year, alongside increased net losses. Despite these setbacks, Data I/O remains debt-free with short-term assets of US$22.2 million comfortably exceeding both short and long-term liabilities. Recent executive changes may impact strategic direction following the termination of its CTO in December 2024. The board is considered experienced with an average tenure of 3.5 years, which may provide stability amidst volatility.

• Click here and access our complete financial health analysis report to understand the dynamics of Data I/O.
• Learn about Data I/O's historical performance here.

Pixelworks (NasdaqGM:PXLW)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Pixelworks, Inc. develops and markets semiconductor and software solutions for mobile, home and enterprise, and cinema markets across the United States, Japan, China, Taiwan, Korea, and Europe with a market cap of $47.40 million.

Operations: The company's revenue is primarily generated from the design, development, marketing, and sale of IC solutions, amounting to $54.19 million.

Market Cap: $47.4M

Pixelworks, Inc., with a market cap of US$47.40 million, grapples with challenges typical of penny stocks, including unprofitability and recent shareholder dilution. Despite reporting Q3 2024 sales of US$9.53 million—a decline from the previous year—its short-term assets exceed both short- and long-term liabilities, providing some financial stability. The company remains debt-free but faces volatility in share price and a Nasdaq compliance issue due to its stock trading below US$1.00 per share. A recent equity offering aims to raise US$10 million as Pixelworks seeks to stabilize operations amidst ongoing financial pressures.

• Get an in-depth perspective on Pixelworks' performance by reading our balance sheet health report here.
• Assess Pixelworks' future earnings estimates with our detailed growth reports.

Ovid Therapeutics (NasdaqGS:OVID)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing impactful medicines for epilepsies and seizure-related neurological disorders in the United States, with a market cap of $77.40 million.

Operations: Ovid Therapeutics generates its revenue from the Pharmaceuticals segment, amounting to $0.63 million.

Market Cap: $77.4M

Ovid Therapeutics, a biopharmaceutical company with a market cap of US$77.40 million, remains pre-revenue with only US$0.63 million in revenue, highlighting typical challenges for penny stocks. Despite its unprofitability and increasing net losses—US$14.01 million in Q3 2024 compared to US$11.25 million the previous year—the company maintains financial stability with short-term assets of US$65.8 million exceeding both short- and long-term liabilities. Ovid is debt-free and has an experienced management team, but its cash runway is limited to less than a year if free cash flow continues to decline at historical rates.

• Navigate through the intricacies of Ovid Therapeutics with our comprehensive balance sheet health report here.
• Explore Ovid Therapeutics' analyst forecasts in our growth report.

Where To Now?

• Jump into our full catalog of 712 US Penny Stocks here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com